Compare TRDA & NODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRDA | NODK |
|---|---|---|
| Founded | 2016 | 1946 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.5M | 286.9M |
| IPO Year | 2021 | 2016 |
| Metric | TRDA | NODK |
|---|---|---|
| Price | $7.08 | $14.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 677.8K | 14.1K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | $25,421,000.00 | ★ $285,050,000.00 |
| Revenue This Year | $39.97 | N/A |
| Revenue Next Year | $50.80 | N/A |
| P/E Ratio | ★ N/A | $23.37 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $12.11 |
| 52 Week High | $16.45 | $14.70 |
| Indicator | TRDA | NODK |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 63.37 |
| Support Level | $5.75 | $13.03 |
| Resistance Level | $7.54 | $14.34 |
| Average True Range (ATR) | 0.50 | 0.30 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 76.46 | 87.38 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.